Skiljevic, Dusan (23487265400)Dusan (23487265400)SkiljevicJeremic, Ivica (36016708800)Ivica (36016708800)JeremicNikolic, Milos (56910382000)Milos (56910382000)NikolicAndrejevic, Sladjana (6701472920)Sladjana (6701472920)AndrejevicSefik-Bukilica, Mirjana (8118591400)Mirjana (8118591400)Sefik-BukilicaStojimirovic, Biljana (7004273397)Biljana (7004273397)StojimirovicBonaci-Nikolic, Branka (10839652200)Branka (10839652200)Bonaci-Nikolic2025-07-022025-07-022013https://doi.org/10.1515/cclm-2012-0521https://www.scopus.com/inward/record.uri?eid=2-s2.0-84882275072&doi=10.1515%2fcclm-2012-0521&partnerID=40&md5=0c4eee0d478598f0a5eb1bfcae56085bhttps://remedy.med.bg.ac.rs/handle/123456789/13833Background : Decreased activity of serum desoxyribonuclease I (DNase I) in systemic lupus erythematosus (SLE) has been reported, but its role as a biomarker in SLE is still unelucidated. Methods : Seventy-seven SLE patients (aged 39.6 ± 13.1 years) were studied for serum DNase I activity, levels of antinuclear (ANA), anti-dsDNA [high-avidity ELISA, conventional ELISA and indirect immunofluorescence (IIF)], anti-nucleosome, anti-histone antibodies, complement components C3 and C4. SLE disease activity was evaluated by disease activity index (SLEDAI-2K). Thirty-five patients were serologically and clinically followed for 3 - 12 months (mean 5.6 ± 2.8). Thirty-seven healthy blood donors were the control group. Results : DNase I activity in SLE patients was lower than in healthy controls (p < 0.01). DNase I activity was in positive correlation with SLEDAI-2K (p < 0.01), levels of ANA, anti-dsDNA, anti-nucleosome and anti-histone antibodies (p < 0.01) and in negative correlation with C3 concentration (p < 0.05). The highest correlation was found between DNase I activity and anti-dsDNA concentrations determined by high-avidity ELISA (r = 0.624), followed by IIF (r = 0.541) and conventional ELISA (r = 0.405). In the follow-up study, DNase I activity also correlated with SLEDAI-2K (p < 0.01). SLE patients with low DNase I activity more frequently had SLE-specific cutaneous lesions (p < 0.05). Conclusions : Monitoring of DNase I activity simultaneously with SLEDAI-2K might be a useful tool in the followup of SLE. An increase of DNase I activity characterized relapse in most SLE patients, although it did not reach the levels of healthy individuals. A decrease of DNase I activity in SLE flare-ups might be a functional biomarker of a subset of patients with specific dysfunction of apoptotic chromatin degradation.Antinuclear antibodiesDesoxyribonuclease IHigh avidity anti-dsDNA antibodiesSLEDAISystemic lupus erythematosus